Table 1 Baseline characteristics of colorectal cancer patients according to SARIFA status.
Cohort 1 | Cohort 2 | |||||||
|---|---|---|---|---|---|---|---|---|
SARIFA status | SARIFA status | |||||||
Characteristic | Total N | Negative | Positive | P | Total N | Negative | Positive | P |
All cases | 1100 (100%) | 774 (70%) | 326 (30%) | 776 (100%) | 533 (69%) | 243 (31%) | ||
Sex | ||||||||
Female | 557 (51%) | 338 (50%) | 169 (52%) | 0.64 | 364 (47%) | 244 (46%) | 120 (49%) | 0.35 |
Male | 543 (49%) | 386 (50%) | 157 (48%) | 412 (53%) | 289 (54%) | 123 (51%) | ||
Age (years) | ||||||||
<65 | 290 (26%) | 189 (24%) | 101 (31%) | 0.075 | 233 (30%) | 151 (28%) | 82 (34%) | 0.15 |
65–75 | 381 (35%) | 277 (36%) | 104 (32%) | 285 (37%) | 194 (36%) | 91 (37%) | ||
>75 | 429 (39%) | 308 (40%) | 121 (37%) | 258 (33%) | 188 (35%) | 70 (29%) | ||
Year of operation | ||||||||
2000–2005 | 342 (31%) | 240 (31%) | 102 (31%) | 0.57 | – | – | – | 0.10 |
2006–2010 | 353 (32%) | 242 (31%) | 111 (34%) | 155 (20%) | 98 (18%) | 57 (23%) | ||
2011–2015 | 405 (37%) | 292 (38%) | 113 (35%) | 218 (28%) | 145 (27%) | 73 (30%) | ||
2016–2020 | – | – | – | 403 (52%) | 290 (54%) | 113 (47%) | ||
Tumour location | ||||||||
Proximal colon | 536 (49%) | 363 (47%) | 173 (53%) | 0.004 | 323 (42%) | 205 (38%) | 118 (49%) | <0.0001 |
Distal colon | 404 (37%) | 281 (36%) | 123 (38%) | 205 (26%) | 127 (24%) | 78 (32%) | ||
Rectum | 160 (15%) | 130 (17%) | 30 (9%) | 248 (32%) | 201 (38%) | 47 (19%) | ||
AJCC disease stage | ||||||||
I | 184 (17%) | 181 (23%) | 3 (1%) | <0.0001 | 187 (24%) | 187 (35%) | 0 (0%) | <0.0001 |
II | 408 (37%) | 327 (42%) | 81 (25%) | 253 (33%) | 183 (34%) | 70 (29%) | ||
III | 355 (32%) | 192 (25%) | 163 (50%) | 251 (32%) | 131 (25%) | 120 (49%) | ||
IV | 153 (14%) | 74 (10%) | 79 (24%) | 85 (11%) | 32 (6%) | 53 (22%) | ||
Tumour grade | ||||||||
Low-grade | 903 (82%) | 667 (86%) | 236 (72%) | <0.0001 | 665 (86%) | 478 (90%) | 187 (77%) | <0.0001 |
High-grade | 197 (18%) | 107 (14%) | 90 (28%) | 111 (14%) | 55 (10%) | 56 (23%) | ||
Lymphovascular invasion | ||||||||
No | 858 (78%) | 667 (86%) | 191 (59%) | <0.0001 | 429 (55%) | 369 (69%) | 60 (25%) | <0.0001 |
Yes | 242 (22%) | 107 (14%) | 135 (41%) | 347 (45%) | 164 (31%) | 183 (75%) | ||
Tumour budding | ||||||||
Grade 1 | 827 (75%) | 647 (84%) | 180 (55%) | <0.0001 | 541 (70%) | 439 (81%) | 111 (46%) | <0.0001 |
Grade 2 | 156 (14%) | 84 (11%) | 72 (22%) | 129 (17%) | 59 (11%) | 70 (29%) | ||
Grade 3 | 117 (11%) | 43 (6%) | 74 (23%) | 106 (14%) | 44 (8%) | 62 (26%) | ||
MMR status | ||||||||
MMR proficient | 931 (85%) | 652 (84%) | 279 (86%) | 0.59 | 652 (84%) | 443 (83%) | 209 (86%) | 0.31 |
MMR deficient | 169 (15%) | 122 (16%) | 47 (14%) | 124 (16%) | 90 (17%) | 34 (14%) | ||
BRAF statusa | ||||||||
Wild-type | 916 (83%) | 657 (85%) | 259 (79%) | 0.026 | 662 (86%) | 462 (88%) | 200 (83%) | 0.072 |
Mutant | 182 (17%) | 115 (15%) | 67 (21%) | 107 (14%) | 65 (12%) | 42 (17%) | ||
Immune cell scoreb | ||||||||
Low | 170 (17%) | 107 (15%) | 63 (21%) | <0.0001 | 114 (15%) | 54 (11%) | 60 (25%) | <0.0001 |
Intermediate | 619 (61%) | 421 (59%) | 198 (65%) | 432 (58%) | 303 (59%) | 129 (54%) | ||
High | 228 (22%) | 185 (26%) | 43 (14%) | 205 (27%) | 156 (31%) | 49 (21%) | ||
